Loading...
•
Mar 29, 2025
Thermo Fisher Q1 2025 Earnings Report
Thermo Fisher reported solid financial results with stable revenue and growth in GAAP EPS.
Key Takeaways
Thermo Fisher delivered a strong Q1 with slight revenue growth, improved GAAP EPS, and robust product innovation in semiconductor and precision medicine sectors.
Revenue reached $10.36 billion, up from $10.34 billion in Q1 2024.
GAAP EPS rose to $3.98 while adjusted EPS increased slightly to $5.15.
Net income improved to $1.51 billion from $1.33 billion a year ago.
Launched several innovative products including the Vulcan Automated Lab and Olink Reveal kits.
Revenue by Segment
Forward Guidance
Thermo Fisher plans to provide updated full-year 2025 financial guidance during the earnings call.
Positive Outlook
- Strong execution amid macroeconomic uncertainty.
- Continued innovation in AI-integrated lab technologies.
- Product launches aligned with customer demand trends.
- Increased dividend and strategic acquisitions.
- Expansion of clinical registries to support data-driven healthcare.
Challenges Ahead
- Flat year-over-year revenue growth.
- Free cash flow dropped significantly YoY.
- Slight decline in adjusted operating income.
- Revenue decline in Laboratory Products & Biopharma segment.
- Continued macroeconomic uncertainty impacting customer spending.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...